Navigation Links
ISTO Technologies Awarded Key Patent for NuQu™ Injectable Therapy for Degenerative Disc Disease
Date:2/7/2011

ST. LOUIS, Feb. 7, 2011 /PRNewswire/ -- ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted the company a key patent covering the primary technology for ISTO's NuQu™ product.  The new patent, issued on February 1, 2011 as Patent # US-7,879,604, covers the method of cultivating juvenile cartilage cells and injecting those cells into a disc nucleus for the treatment of degenerative disc disease.  

NuQu is an injectable cell-based therapy derived from ISTO's cartilage regeneration platform technology.  It is intended for use as an early intervention treatment for patients suffering from lower back pain.  In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to be up to 100 times more efficient in producing cartilage matrix than adult cartilage cells.

"The receipt of this patent is an important milestone for the company and is the result of the hard work of many dedicated people over several years.  We believe that our proprietary juvenile chondrocyte-based technology represents a significant potential new treatment option for patients with chronic lower back pain.  Accordingly, an important part of our strategy is to develop a strong intellectual property base to support our product development efforts. We view this recognition by the USPTO of our novel and unique technology as a significant step forward for the NuQu program and for the Company," said Mitchell Seyedin, Ph.D. President & CEO of ISTO.

The company announced the completion of patient enrollment in the Phase I clinical study for NuQu in October 2010.  The study consists of fifteen (15) patients enrolled at two clinical sites. The company anticipates completing data collection of six-month interim results from the trial in early 2011.  All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapies.

In addition to NuQu, the company's other product derived from its cartilage regeneration platform is DeNovo® ET, a scaffold-free engineered cartilage tissue, intended for the repair of damaged articular cartilage in the knee.  DeNovo® ET is developed in partnership with Zimmer, the world's largest provider of reconstructive solutions, and is currently in clinical trials.

In addition to ISTO's cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute.  InQu combines integrated hyaluronic acid and a resorbable polymer for better handling and biology. The primary target market for InQu is spinal fusion applications.

About ISTO ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.  For additional information on ISTO, please visit our website at www.istotech.com. ISTO Technologies, Inc.

Scott Gill

Chief Financial Officer

(314) 995-6049The Ruth Group

Zack Kubow (investors)

(646) 536-7020

zkubow@theruthgroup.comKimberly Muscara (media)

(646) 536-7011

kmuscara@theruthgroup.com
'/>"/>

SOURCE ISTO Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
2. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
5. Reportlinker Adds European Markets for Assisted Living Technologies
6. PharmAthene Provides Update on Litigation With SIGA Technologies
7. Advanced Assay Technologies and Development Methods
8. Intrasphere Technologies to Help Develop and Deliver Global Partner Training for the Oracle(R) Argus Safety Suite Through Oracle PartnerNetwork
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nopras Technologies, Inc. Achieves ISO 9001:2008 Certification
11. Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... YORK , April 27, 2016 ... OASM ), a developer of a new generation ... announced positive overall survival results for Paclical/Apealea in ... of 789 patients with epithelial ovarian cancer. These ... groups: Paclical/Apealea in combination with carboplatin versus Taxol ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally (which is ... was among the many new lifestyle diet tips offered by nutritionists Pam Bonney and ... of Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
Breaking Medicine News(10 mins):